[go: up one dir, main page]

DK1988913T3 - G-CSF-flydende formulering - Google Patents

G-CSF-flydende formulering

Info

Publication number
DK1988913T3
DK1988913T3 DK07712399T DK07712399T DK1988913T3 DK 1988913 T3 DK1988913 T3 DK 1988913T3 DK 07712399 T DK07712399 T DK 07712399T DK 07712399 T DK07712399 T DK 07712399T DK 1988913 T3 DK1988913 T3 DK 1988913T3
Authority
DK
Denmark
Prior art keywords
csf
polysorbate
liquid formulation
pharmaceutical adjuvants
acetate
Prior art date
Application number
DK07712399T
Other languages
English (en)
Inventor
Michael Mack
Ulrich Kurt Blaschke
Original Assignee
Bioceuticals Arzneimittel Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38226349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1988913(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioceuticals Arzneimittel Ag filed Critical Bioceuticals Arzneimittel Ag
Application granted granted Critical
Publication of DK1988913T3 publication Critical patent/DK1988913T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07712399T 2006-03-01 2007-03-01 G-CSF-flydende formulering DK1988913T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006009437A DE102006009437A1 (de) 2006-03-01 2006-03-01 G-CSF-Flüssigformulierung
PCT/EP2007/051947 WO2007099145A1 (de) 2006-03-01 2007-03-01 G-csf-flüssigformulierung

Publications (1)

Publication Number Publication Date
DK1988913T3 true DK1988913T3 (da) 2009-08-17

Family

ID=38226349

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07712399T DK1988913T3 (da) 2006-03-01 2007-03-01 G-CSF-flydende formulering

Country Status (14)

Country Link
US (1) US20090247450A1 (da)
EP (2) EP1988913B1 (da)
JP (1) JP2009528327A (da)
AT (1) ATE429243T1 (da)
CA (1) CA2644461A1 (da)
CY (1) CY1109223T1 (da)
DE (4) DE202006020194U1 (da)
DK (1) DK1988913T3 (da)
ES (1) ES2326498T3 (da)
PL (1) PL1988913T3 (da)
PT (1) PT1988913E (da)
RU (1) RU2445115C2 (da)
SI (1) SI1988913T1 (da)
WO (1) WO2007099145A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
CN102212019B (zh) 2003-03-14 2015-05-27 蔚所番有限公司 支化水溶性聚合物及其缀合物
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP5743368B2 (ja) 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー ペプチドのｏ結合型グリコシル化
US20080300173A1 (en) * 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
RS52845B (sr) 2007-04-03 2013-12-31 Biogenerix Ag Postupci tretmana korišćenjem glikopegiliranog g-csf
JP5876649B2 (ja) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ ヌクレオチド糖の改良製造法
SI2197919T1 (sl) * 2007-08-27 2014-09-30 Ratiopharm Gmbh Tekoäśa formulacija g-csf konjugata
DE102007040932A1 (de) * 2007-08-27 2009-03-05 Biogenerix Ag Flüssigformulierung von G-CSF
WO2009027076A1 (de) * 2007-08-27 2009-03-05 Biogenerix Ag Flüssigformulierung von g-csf
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
EP2399572A1 (en) * 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE3537708A1 (de) 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
EP0719860B1 (en) 1988-05-13 2009-12-16 Amgen Inc. Process for isolating and purifying G-CSF
DE3835350A1 (de) 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
FR2669646A1 (fr) 1990-11-23 1992-05-29 Lorraine Laminage Procede de traitement d'un effluent aqueux issu d'un procede d'electrozingage, ainsi que procede et installation en comportant application.
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4242919A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
GB9300356D0 (en) * 1993-01-09 1993-03-03 Tbs Eng Ltd Apparatus for assembling battery plates
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
EP1060746A4 (en) * 1998-03-06 2002-06-19 Chugai Pharmaceutical Co Ltd PROTEIN-FREE PREPARATIONS
EP0988861B1 (en) 1998-08-17 2004-03-03 Pfizer Products Inc. Stabilized protein compositions
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
WO2005042024A1 (en) 2003-11-04 2005-05-12 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung

Also Published As

Publication number Publication date
US20090247450A1 (en) 2009-10-01
DE202006020194U1 (de) 2007-12-06
WO2007099145A1 (de) 2007-09-07
DE202007018618U1 (de) 2008-12-11
EP2098243A1 (de) 2009-09-09
CA2644461A1 (en) 2007-09-07
EP1988913A1 (de) 2008-11-12
PT1988913E (pt) 2009-07-16
CY1109223T1 (el) 2014-07-02
JP2009528327A (ja) 2009-08-06
DE102006009437A1 (de) 2007-09-13
ATE429243T1 (de) 2009-05-15
EP1988913B1 (de) 2009-04-22
RU2445115C2 (ru) 2012-03-20
DE502007000649D1 (de) 2009-06-04
SI1988913T1 (sl) 2009-10-31
ES2326498T3 (es) 2009-10-13
PL1988913T3 (pl) 2009-09-30
RU2008138646A (ru) 2010-04-10

Similar Documents

Publication Publication Date Title
DK1988913T3 (da) G-CSF-flydende formulering
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
TW200716202A (en) Pediatric formulation of topiramate
ATE464057T1 (de) Gepufferte dialyselösung
WO2007081579A3 (en) Foam/spray producing compositions and dispensing system therefor
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
WO2014188178A9 (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
NO20080801L (no) Aerosolformulering for inhalering av beta-agonister
PE20081350A1 (es) Sal fumarato de (alfas s, beta r)-6-bromo-alfa-[2(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
CU23367A3 (es) Formulación de moxifloxacino con sal común
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
WO2008020229A3 (en) Antibacterial pyrrolecarboxamides
DK1377164T3 (da) Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo
AR058586A1 (es) Compuesto de 2-carboxitiofeno, formulacion farmaceutica que lo comprende, su uso para la preparacion de un medicamento y combinacion de dicho compuesto con otro agente terapeuticamente activo
WO2006040112A3 (en) Taste-masking pharmaceutical compositions
EP1609473A8 (en) Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria
NO20071636L (no) Flytende allergivaksineformulering for oromukosal administrering
CR9991A (es) Nuevo derivado de pleuromutilina y su uso
WO2009102808A3 (en) Doxorubicin adjuvants to reduce toxicity and methods for using the same
CL2008001282A1 (es) Composicion farmaceutica con actividad antimicrobiana que comprende un aminoacidos n halogenado y un agente antiinflamatorio; uso para prevenir o tratar una infeccion de tejidos, donde dicho tejido es ocular, nasal, seno nasal o dermico o una infeccion respiratoria.
AR045070A1 (es) Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico
WO2006042478A8 (fr) Inhibiteurs de petites molecules de la protease principale des coronavirus, leur preparation et utilisation
WO2007121471A3 (en) Dialkyl ether delivery agents